Epidermal Growth Factor Receptor (EGFR)

Overview

EGFR, the epidermal growth factor receptor, is a transmembrane receptor tyrosine kinase encoded by the EGFR gene. It belongs to the ERBB family of receptors and is activated by ligands such as epidermal growth factor. Upon activation, EGFR triggers intracellular signaling cascades including the PI3K/AKT/mTOR, JAK2/signal transducer and activator of transcription 3 (STAT3), and MAPK pathways, which regulate cell proliferation, survival, migration, differentiation, and tissue repair. Because of this central signaling role, EGFR is a major biological regulator in normal physiology and a prominent therapeutic target in oncology.

Clinically, EGFR is best known for its role in EGFR-mutated non-small cell lung cancer (NSCLC), where activating mutations can drive tumor growth and confer sensitivity to EGFR-targeted tyrosine kinase inhibitors (TKIs). EGFR signaling is also implicated in resistance biology, including bypass signaling through met, interactions with HER2, and receptor stabilization mechanisms involving ubiquitin-dependent degradation. Beyond cancer, EGFR-associated signaling has also been studied in tissue regeneration and wound repair.

Recent Publications Summary

Recent publications demonstrate EGFR's role as a therapeutic target across multiple cancer types and disease contexts, with a particular emphasis on overcoming resistance mechanisms. In non-small-cell lung cancer (NSCLC) harboring EGFR mutations, tyrosine kinase inhibitors remain foundational therapies, with studies evaluating reduced doses of afatinib (30 mg) to improve tolerability in patients requiring dose reductions at standard dosing 42381340Jul. However, histologic transformation to squamous cell carcinoma has emerged as an underrecognized resistance mechanism in EGFR-mutant adenocarcinoma, wherein Rb pathway inactivation—particularly CDKN2A/B deletions combined with AKT and MYC activation—drives acquired resistance to osimertinib 42308331Jun. CRISPR activation screening in autochthonous lung models confirmed strong selection for EGFR activation during tumorigenesis, underscoring its role as a key driver of lung cancer initiation 41999750Apr.

Efforts to overcome EGFR-targeted therapy resistance have prompted development of alternative targeting strategies. Novel bispecific T-cell engagers directed against EGFR were engineered to recognize epitopes distinct from cetuximab and retain affinity for clinically relevant extracellular domain escape variants (including S492R), effectively inducing T cell-mediated cytotoxicity against both wild-type EGFR and resistant tumor cells 42152476May. A modular "plug-and-play" UPTAB platform enabled targeted protein degradation of EGFR and other membrane proteins, achieving near-complete degradation in vitro and approximately 80% tumor growth inhibition in breast cancer xenografts 42138807May. In hepatocellular carcinoma, acquired lenvatinib resistance was attributed to ACSS2-driven palmitoylation of EGFR, which shields the receptor from ubiquitin-dependent degradation and sustains oncogenic signaling; pharmacological ACSS2 inhibition synergized with lenvatinib to overcome resistance 42134048May.

EGFR remains a validated target in other malignancies, with multimodal approaches showing promise. In recurrent or metastatic head and neck squamous cell carcinoma, ficerafusp alfa—a bispecific fusion protein targeting EGFR and CD3—combined with pembrolizumab demonstrated clinical benefit, particularly in HPV-negative disease where elevated EGFR impairs immune cell tumor penetration 42102329May. In esophageal squamous cell carcinoma, epigallocatechin gallate (EGCG) attenuated arecoline-induced migration and invasion through suppression of EGFR/AKT/P38 signaling 42373249Jun. In breast cancer, loss of CB2R–EGFR heterodimer formation drives trastuzumab resistance by promoting a shift toward HER2-EGFR heterodimers; EGFR inhibition restored trastuzumab sensitivity in resistant models 42115409May. Molecular imaging approaches using cetuximab-IRDye800 conjugates have also been developed to visualize EGFR-overexpressing tumors, though temporal dynamics and H-aggregate formation affect photoacoustic and fluorescence signals over time 42090518May.

Beyond oncology, EGFR signaling has been implicated in regenerative and inflammatory diseases. A dual-enzyme cascade protein hydrogel incorporating epidermal growth factor (EGF) fused to collagen-like protein promoted diabetic wound healing by actively remodeling the pathological microenvironment 42289263Jun. Network pharmacology studies identified EGFR as a multi-target node through which the β-adrenergic agonist isoprenaline alleviates diabetic kidney disease via modulation of cGAS-STING pathway signaling 41795784Mar. Additionally, EGFR amplifications were identified as a molecular feature of a distinct subtype of esophageal adenocarcinoma with SMARCA2/4 deficiency, expanding the clinicopathological landscape of EGFR-driven malignancies 42527418Jul.

What Changes, What Holds

1. EGFR is now implicated in resistance states and initiation programs beyond the classic sensitizing-mutation model
NEW DIRECTION Reduced-dose afatinib mainly refines tolerability within the established EGFR-mutant NSCLC treatment framework, but the more consequential finding is that histologic transformation to squamous carcinoma can underlie acquired osimertinib resistance and that Rb-pathway loss with AKT/MYC activation may drive it 42381340Jul42308331Jun. CRISPR activation data also strengthen EGFR’s role as a tumor-initiating driver in lung cancer, extending the baseline’s oncogenic framing 41999750Apr.

2. EGFR is becoming a target for resistance-bypassing and degradation-based strategies
REINFORCES These studies do not replace EGFR-targeted therapy; they extend the baseline’s resistance biology by showing how escape can be countered when extracellular variants evade antibody binding or when receptor stability is preserved. The ACSS2–palmitoylation mechanism in hepatocellular carcinoma fits directly with the overview’s note that ubiquitin-dependent degradation matters for EGFR signaling control 42134048May. The bispecific engager and degradation platform are new modalities, but they support the same therapeutic premise rather than changing it 42152476May42138807May.

3. EGFR’s therapeutic reach now includes immune-engaging and biomarker-guided combinations outside lung cancer
NEW DIRECTION Ficerafusp alfa with pembrolizumab and the imaging work broaden EGFR use into immune redirection and tumor visualization, roles the baseline does not cover 42102329May42090518May. The breast-cancer resistance finding also sharpens the overview’s HER2-bypass theme by showing that loss of CB2R–EGFR heterodimers can favor HER2-EGFR pairing and trastuzumab resistance, with EGFR inhibition restoring sensitivity 42115409May. EGCG’s effects in esophageal squamous cell carcinoma are supportive but mechanistically narrower 42373249Jun.

4. EGFR is being linked to wound repair and inflammatory disease mechanisms beyond oncology
NEW DIRECTION The hydrogel wound-healing work fits the overview’s brief mention of tissue repair but makes that role more actionable by using EGF to actively remodel a diabetic wound microenvironment 42289263Jun. The diabetic kidney disease analysis and the SMARCA2/4-deficient esophageal adenocarcinoma subtype both extend EGFR into disease contexts the baseline does not discuss, so they add breadth rather than contradict prior knowledge 41795784Mar42527418Jul.

Overview update candidates: histologic transformation as resistance; Rb-pathway-linked osimertinib resistance; EGFR as a driver of lung tumor initiation; ACSS2-mediated protection from degradation as a resistance mechanism; EGFR degradation as a therapeutic strategy; EGFR-directed immune engagement in HNSCC; EGFR imaging; CB2R–EGFR heterodimer loss in trastuzumab resistance; EGF-based wound-healing biomaterials; EGFR as a node in diabetic kidney disease; EGFR amplification in SMARCA2/4-deficient esophageal adenocarcinoma.